Studies show that in patients with impaired glucose tolerance, bezafibrate may delay progress to diabetes, and in those with insulin resistance it slowed progress in the HOMA severity marker.
The main effect on cardiovascular morbidity is in patients with the metabolic syndrome, the features of which are attenuated by bezafibrate. Bezafibrate improves markers of combined hyperlipidemia, effectively reducing LDL and triglycerides and improving HDL levels. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL. * Bezafibrate is a fibrate drug used as a lipid-lowering agent to treat hyperlipidemia. Vitamin B1 as Thiamine Tetrahydrofurfuryl Disulfide VitaminB2 as Flavin Mononucleotide + Flavin Adenine Dinucleotide Vitamin B3 as Nicotinamide Adenine Dinucleotide Vitamin B6 as Pyridoxal 5′-phosphate (PLP)
Monosodium Glutamate Salt for taste titillation Hinokitiol for iron uptake in the gut and hemoglobin production * Appetite Stimulation is a mix oriented to those elderly with increasing appetite loss.
0 kommentar(er)
